Acute Lymphoblastic Leukemia research hub
19 indexed studies · 11 currently recruiting
- recruitingPHASE1
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
This study is looking at a new drug called bleximenib in people with a type of blood cancer called acute leukaemia. Researchers want to understand how the body handles this drug.
United Kingdom - recruitingPHASE1, PHASE2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
This study is looking at a medicine called ponatinib for children aged 1 to 17 with certain types of cancer, like leukemia and lymphoma. We want to see how safe it is and how well it works when other treatments haven't helped or aren't suitable.
Belgium · France · Italy - ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive acute lymphoblastic leukemia
This study is looking at two different treatments, obinutuzumab and rituximab, along with standard chemotherapy for adults newly diagnosed with a type of blood cancer called acute lymphoblastic leukaemia. It aims to see which combination works best to put the cancer into remission.
Poland - recruitingPHASE2
Methods of T Cell Depletion Trial (MoTD)
This study compares different ways to prevent a complication called GvHD after stem cell transplants for various blood cancers. It's looking for the best treatment plan to help patients recover well, using common medicines like Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.
United Kingdom - active not recruitingPHASE2
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
This study compares two ways to prepare adults with acute lymphoblastic leukaemia (ALL) for a stem cell transplant. It aims to find out if a slightly stronger treatment can better stop the cancer from coming back, without making the transplant recovery harder.
United Kingdom - recruitingPHASE1
CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
This study is testing a new cell therapy for children and young adults with a type of blood cancer called acute lymphoblastic leukaemia (ALL) that has come back. It aims to see how safe and effective these special cells are, and how long their positive effects might last.
United Kingdom - recruitingPHASE1, PHASE2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
This study is looking at a new medicine called revumenib for different types of leukaemia that have come back or not responded to treatment. It aims to find the right dose and see how well it works and if it's safe for people with certain genetic changes in their leukaemia.
United States · Australia · Canada - recruitingPHASE2, PHASE3
A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
This study looks at new treatments for adults with a type of blood cancer called acute lymphoblastic leukaemia (ALL). It aims to find better ways to use new targeted drugs and bone marrow transplants to improve recovery and long-term health for patients.
France - active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
United States · Australia · Austria - recruitingPHASE3
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
This study looks at a new drug called blinatumomab for babies under one year old with a specific type of leukaemia (blood cancer). The aim is to make treatments better for these tiny patients by adding blinatumomab to their usual care. It's a key step in finding more effective ways to fight this illness.
Argentina · Australia · Austria - recruiting
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
This study is gathering information on adults in the UK with acute lymphoblastic leukaemia (ALL) or similar blood cancers. Doctors want to learn more about how these cancers are diagnosed and treated, and how patients recover. It helps improve future care for people with these conditions, whether or not they're on a specific trial.
Austria · Germany - active not recruitingPHASE1, PHASE2
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This study is testing a new cell therapy called rapcabtagene autoleucel for different types of blood cancers, including certain lymphomas and leukaemias. It aims to see if the treatment is safe, works well, and how best to give it, sometimes with another drug called ibrutinib.
United States · Australia · Austria - active not recruitingPHASE2
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
This study looks at new ways to treat childhood leukaemia and lymphoma. We're testing a new chemotherapy drug called SC-PEG, exploring how to give standard treatments, and investigating ways to prevent infections and bone problems. The goal is to improve care for children with these conditions.
United States · Canada - recruitingPHASE2
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This study looks at a new medicine, Inotuzumab Ozogamicin (InO), for children aged 1 to 17 with a type of blood cancer called Acute Lymphoblastic Leukaemia (ALL) that has come back. It compares InO to a standard treatment to see which works better and is safer.
Austria · Belgium · Czechia - recruitingPHASE1, PHASE2
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
This study looks at blood and bone marrow from children and young people with leukaemia that's come back or is hard to treat. It helps doctors understand the leukaemia better, which could lead to improved treatments and new ways to diagnose and care for young patients.
United States · Australia · Canada - active not recruitingPHASE1, PHASE2
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
This study looks at new drug combinations for babies with a type of blood cancer called acute lymphoblastic leukaemia (ALL). It explores how well new drugs, bortezomib and vorinostat, work with standard treatments and checks for any side effects, aiming to improve treatment outcomes for these infants.
United States · Canada - active not recruitingPHASE1, PHASE2
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
This study is testing a new drug called ziftomenib for people with a type of blood cancer called acute myeloid leukaemia (AML) that has come back or not responded to previous treatments. It's the first time this drug is being used in people.
United States · Belgium · Canada - active not recruitingPHASE3
A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents
This study looks at how best to give a medicine called pegaspargase to children and young people with acute lymphoblastic leukaemia (ALL). It compares different ways of giving the medicine, aiming to find the most effective and safest approach to help treat this type of blood cancer.
France - recruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
Austria · Belgium · Denmark